Related Experiment Video
Updated: May 25, 2026
11:28
Biofunctionalized Prussian Blue Nanoparticles for Multimodal Molecular Imaging Applications
Published on: April 28, 2015
Boronated compounds for imaging guided BNCT applications
Simonetta Geninatti-Crich1, Annamaria Deagostino, Antonio Toppino
1Dipartimento di Chimica Generale e Chimica Organica, Università degli studi di Torino, Via Pietro Giuria, 7, 10125 Torino, Italy.
Anti-Cancer Agents in Medicinal Chemistry
|January 24, 2012
Summary
Boron neutron capture therapy (BNCT) requires precise boron-10 delivery for tumor treatment. Imaging techniques like NMR, PET, and SPECT are crucial for determining boron distribution and improving BNCT efficacy.
Area of Science:
- Oncology
- Nuclear Medicine
- Radiochemistry
Background:
- Boron neutron capture therapy (BNCT) shows promise for tumor treatment by targeting boron-10 ((10)B) in cancer cells.
- Challenges remain in achieving consistent (10)B uptake and accurately measuring tumor-to-blood ratios, hindering widespread clinical adoption.
Purpose of the Study:
- To review the role of advanced imaging techniques in assessing the in vivo biodistribution of BNCT agents.
- To highlight how NMR, PET, and SPECT can enhance the therapeutic efficacy of BNCT.
Main Methods:
- Survey of recent studies (last decade) focusing on imaging BNCT agents.
- Evaluation of Nuclear Magnetic Resonance (NMR), Positron Emission Tomography (PET), and Single-Photon Emission Computed Tomography (SPECT) applications.
Main Results:
- Imaging techniques are increasingly used to determine the in vivo biodistribution of BNCT agents like BPA, BSH, and carborane derivatives.
- These methods offer potential solutions for uncertainties in (10)B concentration measurements.
Conclusions:
- Advanced imaging modalities are vital for optimizing boron delivery and improving the therapeutic index of BNCT.
- Further integration of NMR, PET, and SPECT is expected to advance BNCT as a clinical tool for cancer treatment.
